Under the deal, System Biosciences will convert many of DV Biologics' disease-specific cell types into induced pluripotent stem cell lines.
In clinical studies, the test demonstrated 97.1 percent positive agreement and 100 percent negative agreement with conventional methods of testing for MRSA, AdvanDx said.
1st Base will promote Protoemics International's proteomics services in Singapore, Malaysia, Indonesia, and Thailand.
The companies have integrated HTG's qBead technology for use on the Luminex xMAP multiplexing platform.
The term sheet agreement with GeneDiagnostics would cover marketing for the ColonSentry in Shanghai, Zhejiang, and Jiangsu.
Access will offer its web-based software with the Caliper LabChip GX system as an integrated molecular diagnostic platform.
Novartis Diagnostics will take the Bio-Seeq molecular diagnostic tests for infectious disease through clinical trials and on to commercialization.
Life Technologies will sell the kits for chromosomal abnormalities under the Applied Biosystems name. The agreement, however, does not include the US.
Enzo plans to seek approval for and market MultiGen's antenatal infectious disease tests in New York and in other US regions.
The exclusive sales and marketing agreement covers gene expression tests for inflammatory bowel disease and irritable bowel syndrome.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.